Press Releases

09.03.2020

Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020

08.20.2020

Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

08.07.2020

Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

08.06.2020

Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020

08.05.2020

Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate

08.05.2020

LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer

07.31.2020

Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate

07.28.2020

Pfizer Reports Second-Quarter 2020 Results

07.27.2020

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study

07.22.2020

Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2

07.20.2020

Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data

07.20.2020

Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2